

Freedom of Information Request	FOI 23-650	8 th December 2023
--------------------------------	------------	-------------------------------

Your Request

You requested the following:

1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.
2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)
 - Hemlibra in combination with any Factor VIII
 - NovoEight
 - NovoSeven RT
 - Nuwiq
 - Obizur
 - Refacto AF
 - Any other products
3. For patients treated with Advate in the last three months, please provide:
 - the number of haemophilia A patients treated prophylactically
 - the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)
4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)
 - Hemlibra in combination with any Factor VIII
 - NovoEight
 - NovoSeven RT
 - Nuwiq
 - Obizur
 - Refacto AF
 - Any other products

Our response

1. 10 patients, who have all been classified as mild disease. Please note that we only care for patients who have been classified as mild; any patients classified as severe or moderate patients are cared for at the University Hospital of Wales.
2. One patient has been treated with Advate.

3. No haemophilia A patients have been treated prophylactically in the last 3 months. One haemophilia patient has been treated for other reasons.
4. None